Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
BBB

Ratings ESG MSCI

Ratings Abbott Laboratories: Strengths and Weaknesses

Highlights: Abbott Laboratories
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses: Abbott Laboratories
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • With a 2026 P/E ratio at 29.17 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Rating Financials

Abbott Laboratories SectorSwitzerland

Fundamentals

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

EBIT Margin

Net Margin

Capital Efficiency

ROA

ROCE

ROE

Financial Health

Gearing

Leverage

Capital Intensity

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Abbott Laboratories SectorSwitzerland

Global Valuation

Enterprise Value

EV/Revenue

EV/EBITDA

EV/FCF

Equity Valuation

P/E

PBR

Dividend Yield

EV/EBIT

CAPEX/Revenue

More ratings

Rating Consensus

Abbott Laboratories SectorSwitzerland

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Abbott Laboratories SectorSwitzerland

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Abbott Laboratories SectorSwitzerland

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
178B
BBB
178B
BBB
117B
BBB
60.39B
AA
49.22B
A
48.02B
AAA
33.65B
BBB
28.04B
A
25.46B
AAA
22.5B
BBB
Average 74.1B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Stocks
  3. ABT Stock
  4. ABT Stock
  5. Ratings Abbott Laboratories
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!